BioSim™ Bevacizumab (Human) ELISA Kit

(No reviews yet) Write a Review
Usually Shipped in 5 Working Days
100 Assays
Storage Conditions:
Shipping Conditions:
Gel Pack
Shelf life:
12 months
Frequently bought together:


Bevacizumab is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.BioVision’s BioSim™ Bevacizumab ELISA kit has been developed for specific quantification of Bevacizumab concentration in human serum or plasma with high sensitivity and reproducibility.

Alternate Name: VPF, VEGF, MVCD1, VEGFA, CAS 216974-75-3

Tag Line: A Sandwich ELISA kit for the quantitative measurement of Bevacizumab in human serum or plasma.

Summary: N/A

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for quantitative measurement of Bevacizumab in human serum and plasma

Features & Benefits: • Easy, convenient, sensitive and time-saving method to measure the level of Bevacizumab in human serum and plasma. • Detection Range: 30 - 1000 ng/ml • Sensitivity: 30 ng/ml • Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100) • Recovery rate: 85 – 115% with normal human serum samples with known concentrations • Cross Reactivity: No significant cross-reactivity or interference with other proteins present in native human serum or other therapeutic immunoglobulins.

View AllClose